Bacopa

What Is Bacopa?

Bacopa is an Ayurvedic herb with a long history of use throughout India.

In the past couple of years its popularity has grown a lot for its use as a nootropic supplement.

The herb contains a set of chemicals known as bacosides, which have been shown to provide a list of beneficial actions on the central nervous system and brain.

Traditionally it has been used for memory and a range of nervous-system complaints. Bacopa also has anticonvulsant and anxiolytic actions, and a traditional reputation for anxiety and epilepsy — though anyone taking phenytoin should read the safety note below first.

What Is Bacopa Used For?

Bacopa is used mainly for memory support and cognitive enhancement. Most of the human evidence is in healthy adults and older people, where standardised extracts produce modest gains in memory retention and speed of attention over about 12 weeks — see the research section below. Its popular reputation for treating Alzheimer’s and dementia runs ahead of the data: the one controlled dementia trial, against donepezil, was terminated early and found no significant benefit.

Traditional Uses

Bacopa (AKA brahmi) was commonly used as a brain tonic and to enhance learning ^{28Reference 28Mukherjee et al. · 1966Clinical trialClinical trial on Brahmi}.

In Ayurveda it was used to treat anxiety and epilepsy. ^{29Reference 29Chopra · 1958Chopra’s Indigenous Drugs of India}.

Botanical Information

Bacopa is a member of the plantaginaceae family (plantain family), which includes about 94 genera, and 1900 species, the largest of which is the genus Veronica.

Habitat, Ecology & Distribution

Bacopa prefers wet soil or shallow water. It grows at an incredible range of altitudes, from sea level to 1400 m. ^{30Reference 30Bone et al. · 1996ReviewClinical Applications of Ayurvedic and Chinese Herbs: monographs for the Western herbal practitioner}.

Phytochemistry

The cognitive activity of bacopa is attributed to a family of dammarane-type triterpenoid saponins known collectively as the bacosides. The standardising marker is bacoside A — itself a mixture of bacoside A3, bacopaside II and related glycosides — usually reported together with bacopaside I. Quality extracts are typically standardised to 8–20% total bacosides. ^{27,31,32,33,34,35Reference 27Bacopa monniera · 2004ReviewAlternative Medicine Review, 9(1), 79–85Reference 31Kapoor · 1990CRC Handbook of Ayurvedic Medicinal PlantsReference 32Chakravarty et al. · 2003Bacopasides III–V: three new triterpenoid glycosides from Bacopa monnieraReference 33Hou et al. · 2002Bacopaside III, bacopasaponin G, and bacopasides A, B, and C from Bacopa monnieraReference 34Mahato et al. · 2000Bacopasaponins E and F: two jujubogenin bisdesmosides from Bacopa monnieraReference 35Chakravarty et al. · 2001Bacopaside I and II: two pseudojujubogenin glycosides from Bacopa monniera}.

The plant also contains sterols such as beta-sitosterol and stigmasterol, the triterpene betulinic acid, additional bacopasaponins, flavonoids, and the minor alkaloids brahmine and herpestine ^{27Reference 27Bacopa monniera · 2004ReviewAlternative Medicine Review, 9(1), 79–85}.

Constituent Summary

Figures are percent of dry plant material (whole herb); bacoside content varies markedly with genotype, region and extraction. Many commercial “total bacoside” assays use UV spectrophotometry and run higher than the HPLC ranges below.

Pharmacology & Research

Bacopa monnieri (Brahmi) is one of the better-studied nootropic herbs, and unlike most botanicals its cognitive claim rests on genuine human data: at least nine randomised placebo-controlled trials of chronic dosing, pooled in a 2014 meta-analysis and a 2026 network meta-analysis, converge on a real but modest improvement in memory and speed of attention ^{1,6Reference 1Kongkeaw et al. · 2014Meta-analysisMeta-analysis of randomized controlled trials on cognitive effects of Bacopa monnieri extract — systematic review and meta-analysisView study →Reference 6Tiemtad et al. · 2026Meta-analysisComparative effects of Bacopa monnieri and Ginkgo biloba on cognitive functions — systematic review and network meta-analysisView study →}. Almost all of that human work uses two standardised extracts — CDRI 08 (KeenMind/BacoMonnieri) and BacoMind — so results transfer poorly to teas or raw powder, and the effect sizes are small (mean d ≈ 0.4) ^{1,18Reference 1Kongkeaw et al. · 2014Meta-analysisMeta-analysis of randomized controlled trials on cognitive effects of Bacopa monnieri extract — systematic review and meta-analysisView study →Reference 18Kean et al. · 2016Systematic reviewA systematic review of the Ayurvedic medicinal herb Bacopa monnieri in child and adolescent populations — systematic reviewView study →}. Beneath the cognitive endpoint sits a well-mapped preclinical mechanism: the dammarane-saponin bacosides are antioxidant, anti-inflammatory in brain microglia, and cholinergic-sparing in animal dementia models, but these mechanistic layers have almost never been measured directly in humans ^{8,11,14Reference 8Simpson et al. · 2015ReviewBacopa monnieri as an antioxidant therapy to reduce oxidative stress in the aging brain — reviewView study →Reference 11Valotto Neto et al. · 2024Systematic reviewInvestigating the neuroprotective and cognitive-enhancing effects of Bacopa monnieri — systematic reviewView study →Reference 14Nemetchek et al. · 2017In vitroThe Ayurvedic plant Bacopa monnieri inhibits inflammatory pathways in the brain — in vitro (microglial cell line)View study →}. The most interesting open questions — whether Bacopa helps anxiety, ADHD, or Alzheimer’s beyond healthy-adult memory — remain thinly supported, and its one head-to-head dementia trial against donepezil was terminated early without a clear signal ^{10Reference 10Prabhakar et al. · 2020RCTEfficacy of Bacopa monnieri (Brahmi) and donepezil in Alzheimer’s disease and mild cognitive impairment — randomised double-blind phase-2b trial (terminated)View study →}.

0. Evidence by indication

Support is an experimental score I’m building — a composite weighted by study type (human > animal > in vitro > review) and study volume. It’s a beta: a fast way to rank strength of evidence at a glance, not a validated metric, and I’ll keep honing the formula over time. Each indication name links down to its write-up.

Indication	Support	Rests on
Memory & cognition	████████░░ 80%	9-RCT meta-analysis + network meta-analysis; standardised extracts only, modest effect
Antioxidant	██████░░░░ 60%	Consistent animal/in vitro; proposed driver of cognition, no direct human endpoint
Neuroprotective (Alzheimer’s)	██████░░░░ 56%	Large preclinical base; one human phase-2b vs donepezil terminated, null
Anxiety & stress	██████░░░░ 55%	Human RCT secondary outcomes + acute cortisol drop; small, not primary endpoints
ADHD & child cognition	█████░░░░░ 54%	One RCT (mixed), systematic review, open-label; behavioural endpoint null
Anti-inflammatory	█████░░░░░ 52%	Microglial in vitro + rodent dementia models; no human data
Antidepressant	████░░░░░░ 40%	Rodent models + isolated saponins; constituent-level, no human trial
Anticonvulsant	████░░░░░░ 36%	Rodent GABA-receptor model + Ayurvedic tradition; no controlled human data

1. Memory & cognition

This is the one indication where Bacopa has real human backing. A 2014 meta-analysis of randomised, placebo-controlled trials pooled nine studies (518 subjects, all using standardised extracts dosed ≥12 weeks) and found improved cognition on the Trail-Making B test and a shortened choice reaction time, concluding the herb improves “speed of attention” in particular ^{1Reference 1Kongkeaw et al. · 2014Meta-analysisMeta-analysis of randomized controlled trials on cognitive effects of Bacopa monnieri extract — systematic review and meta-analysisView study →}. Individual RCTs support memory retention specifically: Roodenrys’s double-blind trial (n=76, adults 40–65) found Bacopa slowed the forgetting of newly learned information rather than speeding acquisition ^{4Reference 4Roodenrys et al. · 2002RCTChronic effects of Brahmi (Bacopa monnieri) on human memory — randomised placebo-controlled trialView study →}; Calabrese’s trial in healthy elderly (n=48, 300 mg/day, 12 weeks) improved delayed word recall and Stroop performance ^{2Reference 2Calabrese et al. · 2008RCTEffects of a standardized Bacopa monnieri extract on cognitive performance, anxiety, and depression in the elderly — randomised, double-blind, placebo-controlled trialView study →}; and Morgan’s older-adult trial (n=81, BacoMind 300 mg/day) improved verbal learning and delayed recall on the AVLT ^{3Reference 3Morgan et al. · 2010RCTDoes Bacopa monnieri improve memory performance in older persons? — randomised, placebo-controlled, double-blind trialView study →}. A 2026 network meta-analysis of 29 RCTs (n=2107) ranked high-dose Brahmi (≥600 mg/day) first for working memory, above Ginkgo and placebo, though it found no advantage for attention or processing speed ^{6Reference 6Tiemtad et al. · 2026Meta-analysisComparative effects of Bacopa monnieri and Ginkgo biloba on cognitive functions — systematic review and network meta-analysisView study →}. The signal is consistent, but effect sizes are modest and confined to standardised extracts.

Gap: effects are small, endpoint-specific (retention and attention speed, not global cognition), and demonstrated almost entirely with CDRI 08/BacoMind — there is no evidence a tea or generic powder reproduces them.

2. Antioxidant

Antioxidant activity is the mechanism most often proposed to explain Bacopa’s cognitive effects, and it is well demonstrated preclinically. In streptozotocin-diabetic rats, oral B. monnieri extract restored superoxide dismutase, catalase and glutathione peroxidase activity and reduced lipid peroxidation in brain and kidney ^{7Reference 7Kapoor et al. · 2009AnimalBacopa monnieri modulates antioxidant responses in brain and kidney of diabetic rats — animal modelView study →}. In prenatally stressed rat offspring, a standardised extract (CDRI 08) reversed oxidative and apoptotic markers alongside memory recovery, acting through BDNF and synaptic-protein signalling ^{9Reference 9Sivasangari et al. · 2020AnimalStandardized Bacopa monnieri extract ameliorates learning and memory impairments through synaptic protein, neurogranin, BDNF signaling, and HPA axis in prenatally stressed rat offspring — animal modelView study →}. A 2015 review of the aging brain frames Bacopa as a dietary antioxidant with several plausible modes of action — free-radical scavenging, reduced lipid peroxidation, metal chelation — but explicitly notes that the biological mechanism linking this to human cognitive improvement is still unknown ^{8Reference 8Simpson et al. · 2015ReviewBacopa monnieri as an antioxidant therapy to reduce oxidative stress in the aging brain — reviewView study →}. The bacosides and phenolic constituents are the presumed active antioxidants.

Gap: no human study has measured an antioxidant endpoint (e.g. brain oxidative markers) alongside cognition, so the antioxidant-to-benefit link in people is inferred, not shown.

3. Neuroprotective

Bacopa has an extensive preclinical neuroprotection literature and one instructive human failure. In cell and rodent models it protects cholinergic neurons, reduces β-amyloid deposition, inhibits acetylcholinesterase comparably to donepezil in some assays, and lowers stress-induced hippocampal damage ^{13Reference 13Chaudhari et al. · 2017ReviewNeurocognitive effect of nootropic drug Brahmi (Bacopa monnieri) in Alzheimer’s disease — reviewView study →}. Ethanolic extract inhibits tau aggregation and tau-mediated toxicity in Neuro2a cells, restoring Nrf2 and reducing GSK-3β phosphorylation ^{12Reference 12Dubey et al. · 2023In vitroBacopa monnieri reduces Tau aggregation and Tau-mediated toxicity in cells — in vitroView study →}. A 2024 systematic review of 22 clinical and preclinical reports credits bacoside A and betulinic acid with anti-apoptotic, antioxidant and synapse-restoring actions ^{11Reference 11Valotto Neto et al. · 2024Systematic reviewInvestigating the neuroprotective and cognitive-enhancing effects of Bacopa monnieri — systematic reviewView study →}. But the pivotal human test — a phase-2b RCT comparing Brahmi 300 mg/day against donepezil 10 mg/day in Alzheimer’s and mild cognitive impairment — was terminated early (34 of a planned 48 patients) for slow recruitment and dropout, and found no significant difference in the primary ADAS-Cog outcome ^{10Reference 10Prabhakar et al. · 2020RCTEfficacy of Bacopa monnieri (Brahmi) and donepezil in Alzheimer’s disease and mild cognitive impairment — randomised double-blind phase-2b trial (terminated)View study →}.

Gap: the human trial was underpowered, null on its primary endpoint, and never completed; disease-modifying benefit in dementia is unproven, and the animal-to-human translation has not held up.

4. Anxiety & stress

Human anxiolytic signals exist but come from secondary outcomes, not dedicated trials. In Calabrese’s elderly cognition RCT, combined state-plus-trait anxiety scores and heart rate fell in the Bacopa group and rose in placebo ^{2Reference 2Calabrese et al. · 2008RCTEffects of a standardized Bacopa monnieri extract on cognitive performance, anxiety, and depression in the elderly — randomised, double-blind, placebo-controlled trialView study →}. An acute, double-blind crossover study (n=17) of CDRI 08 at 320 mg and 640 mg found positive mood effects and a reduction in salivary cortisol during a multitasking stress challenge, pointing to a physiological stress-buffering (“adaptogenic”) mechanism ^{16Reference 16Benson et al. · 2014RCTAn acute, double-blind, placebo-controlled cross-over study of 320 mg and 640 mg doses of Bacopa monnieri (CDRI 08) on multitasking stress reactivity and mood — randomised controlled trialView study →}. Preclinically, standardised extract normalised HPA-axis markers (corticosterone, ACTH) in prenatally stressed rats ^{9Reference 9Sivasangari et al. · 2020AnimalStandardized Bacopa monnieri extract ameliorates learning and memory impairments through synaptic protein, neurogranin, BDNF signaling, and HPA axis in prenatally stressed rat offspring — animal modelView study →}. The traditional Ayurvedic use of Brahmi for anxiety long predates these findings, but controlled data remain limited and secondary.

Gap: no adequately powered RCT with anxiety as the primary outcome; the human evidence is a handful of secondary endpoints and one small acute crossover.

5. ADHD & child cognition

Bacopa is one of few herbs tested specifically in children. A 14-week randomised, double-blind, placebo-controlled trial of CDRI 08 in boys aged 6–14 with inattention/hyperactivity (112 recruited, 93 analysed) found no difference on the primary behavioural endpoint, but reported gains in cognitive flexibility, executive function, interpersonal problems and sleep routine ^{17Reference 17Kean et al. · 2022RCTEffects of Bacopa monnieri (CDRI 08) in a population of males exhibiting inattention and hyperactivity aged 6 to 14 years — randomised, double-blind, placebo-controlled trialView study →}. A 2016 systematic review of five paediatric studies calculated small-to-medium effect sizes (mean d=0.42) with consistent improvements in memory sub-domains and attention-deficit domains, and good tolerability (mild side-effects in only ~2.3% of participants) ^{18Reference 18Kean et al. · 2016Systematic reviewA systematic review of the Ayurvedic medicinal herb Bacopa monnieri in child and adolescent populations — systematic reviewView study →}. An open-label study of BacoMind 225 mg/day for six months in 31 children with ADHD reported reduced restlessness and improved self-control, but the uncontrolled design limits its weight ^{19Reference 19Dave et al. · 2014An open-label study to elucidate the effects of standardized Bacopa monnieri extract in the management of symptoms of attention-deficit hyperactivity disorder in childrenView study →}.

Gap: the one blinded RCT was null on its primary behavioural measure; benefits appear on secondary cognitive/sleep outcomes and need replication before ADHD can be called a supported indication.

6. Anti-inflammatory

Bacopa suppresses neuroinflammation in cell and rodent models. In N9 microglial cells, tea, infusion and alkaloid extracts, and bacoside A, inhibited release of the pro-inflammatory cytokines TNF-α and IL-6, and inhibited caspase-1, caspase-3 and matrix metalloproteinase-3 — enzymes tied to CNS inflammation and to tau cleavage in early Alzheimer’s ^{14Reference 14Nemetchek et al. · 2017In vitroThe Ayurvedic plant Bacopa monnieri inhibits inflammatory pathways in the brain — in vitro (microglial cell line)View study →}. In a colchicine-induced rat dementia model, oral extract lowered IL-6, TNF-α, MCP-1, COX-2 and iNOS, reduced BACE-1 activity and amyloid production, and reversed memory deficits, framing the anti-inflammatory action as upstream of the anti-amyloid effect ^{15Reference 15Saini et al. · 2019AnimalBacopa monnieri prevents colchicine-induced dementia by anti-inflammatory action — animal modelView study →}. The traditional use of Bacopa for arthritis is consistent with a systemic anti-inflammatory action, but has not been tested clinically.

Gap: entirely in vitro and rodent; no human inflammatory biomarker or clinical anti-inflammatory outcome has been studied.

7. Antidepressant

Antidepressant activity is constituent-level and preclinical. Triterpene saponins isolated from Bacopa — bacopaside I, bacopaside II and bacopasaponin C — reduced immobility in the mouse forced-swim and tail-suspension tests, the standard rodent antidepressant screens ^{20Reference 20Zhou et al. · 2007AnimalTriterpene saponins from Bacopa monnieri and their antidepressant effects in two mice models — animal modelView study →}. In a reserpine-induced rat depression model, extract restored serotonin, dopamine, noradrenaline, BDNF and Bcl-2 and lowered pro-apoptotic and inflammatory markers, with an effect the authors described as comparable to citalopram ^{21Reference 21Zaazaa et al. · 2022AnimalNeuroprotective role of Bacopa monnieri extract in modulating depression in an experimental rat model — animal modelView study →}. No human antidepressant trial of Bacopa alone exists; the depression-scale improvement seen in Calabrese’s elderly trial was a secondary outcome ^{2Reference 2Calabrese et al. · 2008RCTEffects of a standardized Bacopa monnieri extract on cognitive performance, anxiety, and depression in the elderly — randomised, double-blind, placebo-controlled trialView study →}.

Gap: no human data; the “comparable to citalopram” claim is a rodent behavioural comparison, not a clinical one.

8. Anticonvulsant

Anticonvulsant use rests on Ayurvedic tradition and a rodent mechanism. In pilocarpine-induced temporal-lobe epileptic rats, both B. monnieri and isolated bacoside A reversed the epilepsy-associated down-regulation of hippocampal GABA and GABA(A) receptors and corrected the accompanying deficits in radial-arm and Y-maze performance ^{22Reference 22Mathew et al. · 2011AnimalBehavioral deficit and decreased GABA receptor functional regulation in the hippocampus of epileptic rats: effect of Bacopa monnieri — animal modelView study →}. This maps a plausible GABAergic mechanism, and Brahmi has a long documented use in Ayurveda for epilepsy, but there is no controlled human trial and the classic concern is a pharmacokinetic interaction: Bacopa can reduce plasma phenytoin levels, so self-treatment in epilepsy is specifically cautioned.

Gap: no controlled human data; mechanism is single-model rodent work, and a phenytoin interaction makes unsupervised use in epilepsy potentially unsafe.

Mechanisms

Mechanism	Drives	Key compounds
ROS scavenging, ↑SOD/CAT/GPx, ↓lipid peroxidation	antioxidant, neuroprotective	bacoside A, bacopaside I
TNF-α ↓, IL-6 ↓, COX-2 ↓, caspase-1/3 ↓	anti-inflammatory, neuroprotective	bacoside A
Acetylcholinesterase ↓, cholinergic-neuron protection	memory & cognition, anti-Alzheimer’s	bacosides
β-amyloid ↓, BACE-1 ↓, tau aggregation ↓ (GSK-3β ↓)	neuroprotective (Alzheimer’s)	betulinic acid, bacosides
BDNF ↑, synaptic-protein & 5-HT signalling, HPA-axis normalisation	memory, anxiety/stress, antidepressant	bacosides
GABA / GABA(A) receptor up-regulation	anticonvulsant	bacoside A

Clinical trials

Bacopa has a substantial completed human trial base for cognition (pooled in two meta-analyses), a smaller set for ADHD/child cognition, and one dementia trial (vs donepezil) that was terminated early without a positive result; the antioxidant, anti-inflammatory and antidepressant mechanisms remain preclinical.

Completed	Planned	Terminated	Preclinical
~12+ (cognition, ADHD)	ongoing (child/adult cognition)	1 (phase-2b, Alzheimer’s vs donepezil)	~100s

Last checked: July 2026.

Dosage

In research, Bacopa is almost always given as a standardised extract (CDRI 08 or BacoMind) titrated to a set bacoside content and dosed chronically — most cognitive trials run 300 mg/day for 12 weeks, and a network meta-analysis found ≥600 mg/day best for working memory.

Indication	Preparation	Dose	Est. dried-herb equivalent	Source
Memory (elderly)	Standardised whole-plant extract	300 mg/day, 12 weeks	~0.9–3 g dried herb	2Reference 2Calabrese et al. · 2008RCTEffects of a standardized Bacopa monnieri extract on cognitive performance, anxiety, and depression in the elderly — randomised, double-blind, placebo-controlled trialView study →
Memory (older adults)	BacoMind standardised extract	300 mg/day, 12 weeks	~0.9–3 g dried herb	3Reference 3Morgan et al. · 2010RCTDoes Bacopa monnieri improve memory performance in older persons? — randomised, placebo-controlled, double-blind trialView study →
Working memory (healthy adults)	Standardised extract (network MA)	≥600 mg/day for best effect	~1.8–6 g dried herb	6Reference 6Tiemtad et al. · 2026Meta-analysisComparative effects of Bacopa monnieri and Ginkgo biloba on cognitive functions — systematic review and network meta-analysisView study →
Acute stress / mood	CDRI 08	320–640 mg single dose	— (acute, marker-standardised)	16Reference 16Benson et al. · 2014RCTAn acute, double-blind, placebo-controlled cross-over study of 320 mg and 640 mg doses of Bacopa monnieri (CDRI 08) on multitasking stress reactivity and mood — randomised controlled trialView study →
ADHD / child cognition	CDRI 08	~300 mg/day, 14 weeks	— (paediatric, marker-standardised)	17Reference 17Kean et al. · 2022RCTEffects of Bacopa monnieri (CDRI 08) in a population of males exhibiting inattention and hyperactivity aged 6 to 14 years — randomised, double-blind, placebo-controlled trialView study →
ADHD (open-label)	BacoMind	225 mg/day, 6 months	—	19Reference 19Dave et al. · 2014An open-label study to elucidate the effects of standardized Bacopa monnieri extract in the management of symptoms of attention-deficit hyperactivity disorder in childrenView study →

Est. dried-herb equivalent assumes standardised extracts run ~20% bacosides against ~2–6.6% in dried whole herb, so a 300 mg extract dose (~60 mg bacosides) implies roughly 0.9–3 g of dried herb. This is a guide on a stated assumption, not a conversion factor, and never a recommendation; bacoside content varies severalfold by source.

Traditional Dosage

Western herbal practice uses a whole-plant liquid extract; Ayurveda uses the whole-herb powder or Brahmi ghee as a medhya rasayana (brain tonic). These whole-herb doses are not interchangeable with the standardised-extract doses in the trials above.

System	Preparation	Dose
Western herbal	Liquid extract (1:2)	30–60 mL/week (~4.5–8.5 mL/day)
Western herbal	Dried herb (tincture / infusion)	~5–12 g/day dried-herb equivalent
Ayurveda	Whole-herb powder / Brahmi ghee	Traditional brain tonic; dose by practitioner

Safety

Bacopa is generally well tolerated in human trials, with the most consistent adverse effects being gastrointestinal — increased stool frequency, abdominal cramps and nausea — attributed to its cholinergic action ^{3,18Reference 3Morgan et al. · 2010RCTDoes Bacopa monnieri improve memory performance in older persons? — randomised, placebo-controlled, double-blind trialView study →Reference 18Kean et al. · 2016Systematic reviewA systematic review of the Ayurvedic medicinal herb Bacopa monnieri in child and adolescent populations — systematic reviewView study →}. A subchronic toxicity study in rats established a no-observed-adverse-effect level of 500 mg/kg/day with no organ toxicity, consistent with the low toxicity rating ^{23Reference 23Joshua Allan et al. · 2007AnimalSafety evaluation of a standardized phytochemical composition extracted from Bacopa monnieri in Sprague–Dawley rats — animal toxicologyView study →}. The clinically important concern is drug interactions: in vitro, standardised Bacopa extract inhibits the cytochrome-P450 enzymes CYP3A4, CYP2C9, CYP2C19 and CYP1A2, with the strongest effect expected in the gut, so caution is warranted when co-administered with drugs metabolised by these enzymes ^{24Reference 24Ramasamy et al. · 2014In vitroInhibition of human cytochrome P450 enzymes by Bacopa monnieri standardized extract and constituents — in vitroView study →}. A published case report describes suspected cholinergic toxicity when a Bacopa-containing supplement was taken alongside the muscarinic agonist cevimeline ^{25Reference 25Acquarulo et al. · 2022Case reportSuspected cholinergic toxicity due to cevimeline hydrochloride and Bacopa monnieri interaction — case reportView study →}, and Bacopa is traditionally cautioned against in people taking phenytoin because it can lower plasma phenytoin levels — directly relevant given its traditional anticonvulsant use. An animal study found Bacopa raised thyroxine (T4) by ~41%, suggesting it may act as a thyroid stimulant and should be used carefully in people with thyroid conditions or on thyroid medication ^{26Reference 26Kar et al. · 2002AnimalRelative efficacy of three medicinal plant extracts in the alteration of thyroid hormone concentrations in male mice — animal modelView study →}. These interaction signals are mostly in vitro or single-report, and no dedicated clinical interaction trial has been done.

Pregnancy & lactation

Not established — insufficient human data. Bacopa has not been evaluated for safety in human pregnancy or lactation, and no controlled human reproductive-toxicity data exist. One narrative review notes that animal studies reported reduced fertility in male rats (libido unaffected) with no clear evidence of genotoxicity or teratogenicity, but this does not establish human safety ^{13Reference 13Chaudhari et al. · 2017ReviewNeurocognitive effect of nootropic drug Brahmi (Bacopa monnieri) in Alzheimer’s disease — reviewView study →}. Given its cholinergic and thyroid-modulating activity and the absence of pregnancy-specific research, avoid during pregnancy and breastfeeding unless directed by a qualified practitioner.

References

1. Kongkeaw, C., Dilokthornsakul, P., Thanarangsarit, P., Limpeanchob, N., & Norman Scholfield, C. (2014). Meta-analysis of randomized controlled trials on cognitive effects of Bacopa monnieri extract — systematic review and meta-analysis. Journal of Ethnopharmacology, 151(1), 528–535. https://pubmed.ncbi.nlm.nih.gov/24252493/
2. Calabrese, C., Gregory, W. L., Leo, M., Kraemer, D., Bone, K., & Oken, B. (2008). Effects of a standardized Bacopa monnieri extract on cognitive performance, anxiety, and depression in the elderly — randomised, double-blind, placebo-controlled trial. Journal of Alternative and Complementary Medicine, 14(6), 707–713. https://pubmed.ncbi.nlm.nih.gov/18611150/
3. Morgan, A., & Stevens, J. (2010). Does Bacopa monnieri improve memory performance in older persons? — randomised, placebo-controlled, double-blind trial. Journal of Alternative and Complementary Medicine, 16(7), 753–759. https://pubmed.ncbi.nlm.nih.gov/20590480/
4. Roodenrys, S., Booth, D., Bulzomi, S., Phipps, A., Micallef, C., & Smoker, J. (2002). Chronic effects of Brahmi (Bacopa monnieri) on human memory — randomised placebo-controlled trial. Neuropsychopharmacology, 27(2), 279–281. https://pubmed.ncbi.nlm.nih.gov/12093601/
5. Brimson, J. M., Brimson, S., Prasanth, M. I., Thitilertdecha, P., Malar, D. S., & Tencomnao, T. (2021). The effectiveness of Bacopa monnieri as a nootropic, neuroprotective, or antidepressant supplement: analysis of the available clinical data — systematic review. Scientific Reports, 11(1), 596. https://pubmed.ncbi.nlm.nih.gov/33436817/
6. Tiemtad, P., Ingkaninan, K., Temkitthawon, P., et al. (2026). Comparative effects of Bacopa monnieri and Ginkgo biloba on cognitive functions — systematic review and network meta-analysis. Phytomedicine, 153, 157915. https://pubmed.ncbi.nlm.nih.gov/41678913/
7. Kapoor, R., Srivastava, S., & Kakkar, P. (2009). Bacopa monnieri modulates antioxidant responses in brain and kidney of diabetic rats — animal model. Environmental Toxicology and Pharmacology, 27(1), 62–69. https://pubmed.ncbi.nlm.nih.gov/21783922/
8. Simpson, T., Pase, M., & Stough, C. (2015). Bacopa monnieri as an antioxidant therapy to reduce oxidative stress in the aging brain — review. Evidence-Based Complementary and Alternative Medicine, 2015, 615384. https://pubmed.ncbi.nlm.nih.gov/26413126/
9. Sivasangari, K., & Rajan, K. E. (2020). Standardized Bacopa monnieri extract ameliorates learning and memory impairments through synaptic protein, neurogranin, BDNF signaling, and HPA axis in prenatally stressed rat offspring — animal model. Antioxidants, 9(12), 1229. https://pubmed.ncbi.nlm.nih.gov/33291595/
10. Prabhakar, S., Vishnu, V. Y., Modi, M., et al. (2020). Efficacy of Bacopa monnieri (Brahmi) and donepezil in Alzheimer’s disease and mild cognitive impairment — randomised double-blind phase-2b trial (terminated). Annals of Indian Academy of Neurology, 23(6), 767–773. https://pubmed.ncbi.nlm.nih.gov/33688125/
11. Valotto Neto, L. J., Reverete de Araujo, M., Moretti Junior, R. C., et al. (2024). Investigating the neuroprotective and cognitive-enhancing effects of Bacopa monnieri — systematic review. Antioxidants, 13(4), 393. https://pubmed.ncbi.nlm.nih.gov/38671841/
12. Dubey, T., Kushwaha, P., Thulasiram, H. V., Chandrashekar, M., & Chinnathambi, S. (2023). Bacopa monnieri reduces Tau aggregation and Tau-mediated toxicity in cells — in vitro. International Journal of Biological Macromolecules, 234, 123171. https://pubmed.ncbi.nlm.nih.gov/36716837/
13. Chaudhari, K. S., Tiwari, N. R., Tiwari, R. R., & Sharma, R. S. (2017). Neurocognitive effect of nootropic drug Brahmi (Bacopa monnieri) in Alzheimer’s disease — review. Annals of Neurosciences, 24(2), 111–122. https://pubmed.ncbi.nlm.nih.gov/28588366/
14. Nemetchek, M. D., Stierle, A. A., Stierle, D. B., & Lurie, D. I. (2017). The Ayurvedic plant Bacopa monnieri inhibits inflammatory pathways in the brain — in vitro (microglial cell line). Journal of Ethnopharmacology, 197, 92–100. https://pubmed.ncbi.nlm.nih.gov/27473605/
15. Saini, N., Singh, D., & Sandhir, R. (2019). Bacopa monnieri prevents colchicine-induced dementia by anti-inflammatory action — animal model. Metabolic Brain Disease, 34(2), 505–518. https://pubmed.ncbi.nlm.nih.gov/30604025/
16. Benson, S., Downey, L. A., Stough, C., Wetherell, M., Zangara, A., & Scholey, A. (2014). An acute, double-blind, placebo-controlled cross-over study of 320 mg and 640 mg doses of Bacopa monnieri (CDRI 08) on multitasking stress reactivity and mood — randomised controlled trial. Phytotherapy Research, 28(4), 551–559. https://pubmed.ncbi.nlm.nih.gov/23788517/
17. Kean, J. D., Downey, L. A., Sarris, J., Kaufman, J., Zangara, A., & Stough, C. (2022). Effects of Bacopa monnieri (CDRI 08) in a population of males exhibiting inattention and hyperactivity aged 6 to 14 years — randomised, double-blind, placebo-controlled trial. Phytotherapy Research, 36(2), 996–1012. https://pubmed.ncbi.nlm.nih.gov/35041248/
18. Kean, J. D., Downey, L. A., & Stough, C. (2016). A systematic review of the Ayurvedic medicinal herb Bacopa monnieri in child and adolescent populations — systematic review. Complementary Therapies in Medicine, 29, 56–62. https://pubmed.ncbi.nlm.nih.gov/27912958/
19. Dave, U. P., Dingankar, S. R., Saxena, V. S., et al. (2014). An open-label study to elucidate the effects of standardized Bacopa monnieri extract in the management of symptoms of attention-deficit hyperactivity disorder in children. Advances in Mind-Body Medicine, 28(2), 10–15. https://pubmed.ncbi.nlm.nih.gov/24682000/
20. Zhou, Y., Shen, Y. H., Zhang, C., Su, J., Liu, R. H., & Zhang, W. D. (2007). Triterpene saponins from Bacopa monnieri and their antidepressant effects in two mice models — animal model. Journal of Natural Products, 70(4), 652–655. https://pubmed.ncbi.nlm.nih.gov/17343408/
21. Zaazaa, A. M., Daoud, N. N., El-Gendy, O. A., & Al-Shafei, A. I. (2022). Neuroprotective role of Bacopa monnieri extract in modulating depression in an experimental rat model — animal model. Journal of Affective Disorders, 308, 229–235. https://pubmed.ncbi.nlm.nih.gov/35413358/
22. Mathew, J., Gangadharan, G., Kuruvilla, K. P., & Paulose, C. S. (2011). Behavioral deficit and decreased GABA receptor functional regulation in the hippocampus of epileptic rats: effect of Bacopa monnieri — animal model. Neurochemical Research, 36(1), 7–16. https://pubmed.ncbi.nlm.nih.gov/20821261/
23. Joshua Allan, J., Damodaran, A., Deshmukh, N. S., Goudar, K. S., & Amit, A. (2007). Safety evaluation of a standardized phytochemical composition extracted from Bacopa monnieri in Sprague–Dawley rats — animal toxicology. Food and Chemical Toxicology, 45(10), 1928–1937. https://pubmed.ncbi.nlm.nih.gov/17560704/
24. Ramasamy, S., Kiew, L. V., & Chung, L. Y. (2014). Inhibition of human cytochrome P450 enzymes by Bacopa monnieri standardized extract and constituents — in vitro. Molecules, 19(2), 2588–2601. https://pubmed.ncbi.nlm.nih.gov/24566323/
25. Acquarulo, B., Tandon, P., & Macica, C. M. (2022). Suspected cholinergic toxicity due to cevimeline hydrochloride and Bacopa monnieri interaction — case report. Journal of Medical Case Reports, 16(1), 253. https://pubmed.ncbi.nlm.nih.gov/35765109/
26. Kar, A., Panda, S., & Bharti, S. (2002). Relative efficacy of three medicinal plant extracts in the alteration of thyroid hormone concentrations in male mice — animal model. Journal of Ethnopharmacology, 81(2), 281–285. https://pubmed.ncbi.nlm.nih.gov/12065164/
27. Bacopa monniera. Monograph. (2004). Alternative Medicine Review, 9(1), 79–85.
28. Mukherjee, G. D., & Dey, C. D. (1966). Clinical trial on Brahmi. I. Journal of Experimental Medical Sciences, 10(1), 5.
29. Chopra, R. N. (1958). Chopra’s Indigenous Drugs of India. UN Dhur & Sons, Calcutta.
30. Bone, K., & Morgan, M. (1996). Clinical Applications of Ayurvedic and Chinese Herbs: monographs for the Western herbal practitioner. Phytotherapy Press.
31. Kapoor, L. D. (1990). CRC Handbook of Ayurvedic Medicinal Plants. CRC Press.
32. Chakravarty, A. K., Garai, S., Masuda, K., Nakane, T., & Kawahara, N. (2003). Bacopasides III–V: three new triterpenoid glycosides from Bacopa monniera. Chemical and Pharmaceutical Bulletin, 51(2), 215–217.
33. Hou, C. C., Lin, S. J., Cheng, J. T., & Hsu, F. L. (2002). Bacopaside III, bacopasaponin G, and bacopasides A, B, and C from Bacopa monniera. Journal of Natural Products, 65(12), 1759–1763.
34. Mahato, S. B., Garai, S., & Chakravarty, A. K. (2000). Bacopasaponins E and F: two jujubogenin bisdesmosides from Bacopa monniera. Phytochemistry, 53(6), 711–714.
35. Chakravarty, A. K., Sarkar, T., Masuda, K., Shiojima, K., Nakane, T., & Kawahara, N. (2001). Bacopaside I and II: two pseudojujubogenin glycosides from Bacopa monniera. Phytochemistry, 58(4), 553–556.